AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Comparison of two nucleic acid extraction and testing systems for HCMV-DNA detection and quantitation on whole blood specimens from transplant patients.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/146434> since

Published version:

DOI:10.1016/j.jviromet.2013.07.042

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

UNIVERSITÀ DEGLI STUDI DI TORINO

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in JOURNAL OF VIROLOGICAL METHODS, 193, 2013, 10.1016/j.jviromet.2013.07.042.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>), 10.1016/j.jviromet.2013.07.042.

The definitive version is available at:

<http://www.sciencedirect.com/science/article/pii/S0166093413003121>

1COMPARISON OF TWO NUCLEIC ACID EXTRACTION AND TESTING SYSTEMS
2FOR HCMV-DNA DETECTION AND QUANTITATION ON WHOLE BLOOD
3SPECIMENS FROM TRANSPLANT PATIENTS

4
5Cristina Costa^{1,#}, Samantha Mantovani¹, Cinzia Balloco¹, Francesca Sidoti¹, Fabrizio Fop², Rossana
6Cavallo¹.

7¹Microbiology and Virology Unit; ²Nephrology Unit, Azienda Ospedaliera Città della Salute e della
8Scienza di Torino; Turin, Italy.

9
10
11
12

13# **Corresponding author**

14**Cristina Costa**

15e-mail address: cristina.costa@unito.it; ccosta2@cittadellasalute.to.it

16Tel.: +39(11)6705630-5640; fax: +39(11)6705648

17
18
19
20

21Abstract

22Quantitative detection of human cytomegalovirus (HCMV) DNA on whole blood is currently the
23primary choice for virological monitoring in transplant patients and for determining the appropriate
24antiviral strategy, however specific issues of variability remain in terms of extraction methods,
25amplification efficiency, and variability. This study compared the performance characteristics of
26two nucleic acid extraction and testing systems for HCMV-DNA quantitation, the artus® CMV QS-
27RGQ kit, associated with a fully automated DNA extraction and assay set up by Qiagen (system 1)
28and the Q-CMV Real Time Complete kit by Nanogen, associated with a semiautomated nucleic
29acid extraction system by Biomérieux (system 2) in 189 specimens from transplant patients and 10
30from 2012 HCMV Quality Control for Molecular Diagnostics (QCMD). The two systems exhibited
31a 80.4% concordance. Differences between the two systems were within $\pm 1 \log_{10}$ copies/ml of the
32averaged $\log_{10}$ results for 88.9% of the tested specimens. For all qualitatively discordant specimens,
33mean viral load was $\leq 3 \log_{10}$ copies/ml. Considering viral load measurement, system 1 gave earlier
34positives than system 2, with a 14.8% of specimens resulted positive at low viral loads with system
351 and negative with system 2. In QCMD specimens, difference was below $0.7 \log_{10}$ copies/ml for
36both the systems.

37In conclusion, the two systems provided reliable and comparable results. Some specific
38performance characteristic and automation could be taken into account in terms of less hands of
39time, fewer errors and reliability.

40

41

42**Keywords:** human cytomegalovirus; nucleic acid; extraction; quantitative PCR; efficiency;
43variability

441. Introduction

45 Human cytomegalovirus (HCMV) is an important viral pathogen in both solid organ transplant and
46 hematopoietic stem cell transplant recipients in terms of morbidity and mortality. The frequency of
47 HCMV infection and disease in the post-transplant period depends on the interaction of factors
48 related to the host, virus and transplantation practices, with HCMV serostatus being considered the
49 single most important predictor of disease. Among virus-related factors, the development of HCMV
50 disease has been directly related to the degree of viral replication. Management of HCMV disease
51 varies considerably among transplant centres. A panel of experts on HCMV and solid
52 organ/hematopoietic stem cell transplant was convened to develop international guidelines for the
53 management of HCMV including diagnostics, immunology, prevention, and treatment (Kotton et
54 al., 2010; Zaia et al., 2009). Currently, the diagnosis of HCMV replication and disease in solid
55 organ and hematopoietic stem cell transplant patients can be performed using different methods,
56 including histopathological analysis, quantitative pp65-antigenaemia in peripheral blood leukocytes
57 and quantitative nucleic acid testing. Quantitative detection of HCMV-DNAemia by real-time PCR
58 is currently the primary choice for virological monitoring of HCMV infection in transplant patients;
59 in fact, HCMV-DNA quantitation provides sensitive and specific data for viral detection as well as
60 monitoring the development and course of infection, thus being fundamental for determining the
61 appropriate antiviral strategy. A relevant issue in HCMV routine diagnostics is the interassay
62 quantitation variability (Hirsch et al., 2013; Lilleri et al., 2009), possibly complicating the clinical
63 management and therapeutic decision process in patients evaluated in different laboratories.
64 Recently, the first World Health organization international standard for HCMV quantitative nucleic
65 acid amplification-based assays has been made available (Freyer et al., 2010). Although the
66 availability of the international standard should contribute to improve interassay agreement, specific
67 issues of variability remain in terms of extraction methods and DNA elution, amplification
68 efficiency, and operator-dependent variability (Hirsch et al., 2013; Kraft et al., 2012).

69The aim of this study was to assess the performance characteristics of two nucleic acid extraction
70and testing systems for HCMV-DNA quantitation, the artus® CMV QS-RGQ kit by Qiagen,
71(Hilden, Germany) associated with a fully automated DNA extraction and assay set up by Qiagen
72and the Q-CMV Real Time Complete kit by Nanogen, Elitech Group (Milan, Italy) associated with
73a semiautomated nucleic acid extraction system by Biomérieux (Marcy l'Etoile, France). Using
74whole blood clinical specimens from transplant patients, the two systems were compared and the
75potential clinical implications were evaluated.

762. **Materials and methods**

772.1. *Clinical specimens*

78One-hundred-fifty-six patients referred to the Virology Unit of the Azienda Ospedaliera Città della
79Salute e della Scienza di Torino, Italy, for routine HCMV load testing (90 solid organ transplant
80recipients and 66 hematopoietic stem cell transplant recipients) were included in the study. One-
81hundred-eighty-nine specimens of whole blood (EDTA tubes) were collected between January and
82June 2012. Ten HCMV quality control specimens (Quality Control for Molecular Diagnostics
83-QCMD- 2012 CMV panel) were also processed.

842.2 *Study design*

85Two nucleic acid extraction and testing systems for HCMV-DNA were evaluated: the artus® CMV
86QS-RGQ kit (Qiagen), a commercial real-time PCR for HCMV-DNA associated with a fully
87automated DNA extraction from whole blood (Qiasymphony, Qiagen) and automated assay set up –
88system 1 - and the Q-CMV Real Time Complete kit, a commercial real-time PCR (Nanogen,
89Elitech Group) associated with a semiautomated nucleic acid extraction system from whole blood
90(Easymag, Biomérieux) and manual assay set up – system 2. Currently, the Q-CMV Real Time
91Complete kit, validated for EasyMAG extraction system by the manufacturer, is the routinely used
92method.

93For system 1, nucleic acid extraction was performed according to the manufacturer's instructions;
94nucleic acid was purified with the QIASymphony DNA Mini kit on the QIASymphony instrument
95(Qiagen). Two-hundred microliters of whole blood were concentrated into a 60-µl eluate, and a 20
96µl aliquot was used for the PCR on the real-time PCR cyclor Rotor-Gene Q (Qiagen). The artus®
97CMV QS-RGQ kit targets the major immediate early (MIE) CMV gene. The reaction volume was
9850-µl (20 µl of eluate plus 30 µl of master mix). Analytical sensitivity, as reported by the
99manufacturer, considering purification from whole blood (using the QIASymphony DNA Mini kit)
100and the use of artus® CMV QS-RGQ kit on the Rotor-Gene Q, is 164.55 copies/ml.

101For system 2, nucleic acid was purified with the NucliSENS® EasyMAG® instrument
102(Biomérieux), using the NucliSENS ® Nucleic Acid Extraction Reagents, according to the
103manufacturer's instructions.

104One-hundred microliters of whole blood were concentrated into a 50-µl eluate, and a 5µl aliquot
105was used for PCR assay on the 7500 Real-Time PCR System (Applied Biosystems, Cheshire,
106United Kingdom). The Q-CMV Real Time Complete kit manufactured for Cepheid by Nanogen
107Advanced Diagnostics S.r.L. is specific for the exon 4 region of the CMV MIE gene (major
108immediate early HCMVUL123). The reaction volume was 25 µl (5 µl of eluate plus 20 µl of master
109mix). The limit of detection of the Q-CMV real time kit is 158 copies/ml, as reported by the
110manufacturer. The main technical features of the two systems are summarized in Table 1.

1112.3. *Statistical analysis*

112The correlation between the two systems was determined by linear regression analysis and mean
113differences in quantitation for averaged logs by the Bland-Altman plot. Only viral loads positive by
114both assays were represented on the Bland-Altman graphs. Differences were considered significant
115for p value <0.05.

116

117

1183. Results

119The performance of the two systems was assessed and compared on 189 whole blood specimens
120from 156 transplant recipients undergoing routine testing in the first year post-transplantation.
121System 1 and system 2 detected HCMV-DNA in 118 and 99 samples, respectively, with a 80.4%
122concordance. In particular, 62/189 (32.8%) were concordantly negative by both systems; 90/189
123(47.6%) concordantly positive; 28/189 (14.8%) positive by system 1 and negative by system 2; and
1249/189 (4.8%) positive by system 2 and negative by system 1 (Table 2). For the 90 specimens that
125were positive by both tests, the population mean (SD) was 4.25 (4.58) $\log_{10}$ copies/ml with system 1
126and 4.06 (4.29) $\log_{10}$ copies/ml with system 2. For all the specimens that were qualitatively
127discordant (by one of the two systems), mean viral load was lower or equal to 3 $\log_{10}$ copies/ml.
128By referring to the 90 specimens that were concordantly positive, the correlation value between the
129two systems was $r = 0.597$ (Fig. 1). Bland-Altman analysis showed that differences between the two
130systems were within $\pm 1 \log_{10}$ copies/ml of the averaged $\log_{10}$ results for 88.9% of the tested
131specimens (Fig. 2). Table 3 depicts the HCMV load results for the 10 specimens from the QCMD
1322012 HCMV proficiency panel. The sample for which a negative result was expected was found
133negative by the two systems, whereas for the positive specimens the difference was below 0.7 $\log_{10}$
134copies/ml for both the systems (mean $\Delta\log_{10}$ 0.1566 for system 1 and 0.2288 for system 2).

1354. Discussion

136The automation of nucleic acid extraction and availability of commercial real-time quantitative PCR
137assays have the potential to improve the agreement and clinical usefulness of HCMV-DNA
138measurement in routine transplant settings, thus promoting standardization across laboratories and
139enabling correlation with clinical study results.

140In the present study, the HCMV –DNA load results obtained by two nucleic acid extraction and
141testing systems have been compared. Overall, both systems appear as reliable and user-friendly for
142monitoring HCMV-DNAemia in transplant recipients.

143The two systems exhibited an overall concordance of 80.4% in qualitative terms. Considering
144specimens that were positive by both the systems, the mean viral load differs of 0.19 log₁₀
145copies/ml. On the other hand, when considering specimens that were qualitatively discordant, mean
146viral load was lower or equal to 3 log₁₀ copies/ml.

147Considering viral load measurement, system 1 gave earlier positives than system 2, as evidenced by
148the evaluation of frequency distribution for different log of viral load (not shown), with
149approximately 15% of specimens resulted positive at low viral loads with system 1 and negative
150with system 2. This is likely to be attributable to the fact that system 1 employs more blood derived
151material in comparison to system 2, thus improving the recovery ability in the nucleic acid
152purification phase. This should be taken into account in the monitoring of transplant recipients as it
153could be useful for prompt identification of patients at risk and could allow for rechecking on a
154subsequent specimen within a short period.

155Monitoring of HCMV-DNAemia has become critical for early identification of viral reactivation
156with the aim of reducing the occurrence of systemic and/or organ disease in the post-transplant
157setting and of evaluating the response to antiviral therapy. Although both antiviral prophylaxis and
158pre-emptive therapy are useful strategies to prevent the occurrence of HCMV disease, the potential
159exposure to adverse events associated with prolonged antiviral drug administration has limited the
160utility of a universal prophylaxis strategy, thus suggesting its adoption only in high risk patients,

161such as HCMV-seropositive donor/HCMV-seronegative recipients. On the other hand, viral load
162monitoring for guiding pre-emptive therapy is critical. The adoption of a pre-emptive strategy
163appears advantageous in terms of number of treated patients, appropriateness of antiviral
164administration and duration of therapy, costs, risks of onset of drug adverse events, as well as
165emergence of drug-resistant strains.

166By using the Bland-Altman analysis, differences between the two systems were within $\pm 1 \log_{10}$
167copies/ml of the averaged $\log_{10}$ results for almost 89% of the tested specimens. The occurrence of
168constant and variable quantitation differences among nucleic acid assays underlines the usefulness
169of a general quantitative standardization, that could also allow for a better evaluation of specific
170differences only related to different technical performances of the assays.

171From an organizational point of view, system 1, being a full-automated system, provides benefits
172over a semi-automated system, in terms of less hands of time, fewer errors and reliability, that are
173relevant factors in a high-routine laboratory. It is to note that the present study compared two
174testing systems with two different extraction methods, therefore it is not known whether the
175differences came from the nucleic acid purification techniques or from the two HCMV tests or
176probably both; further studies including cross-test of both extraction methods with both PCR
177systems could help to clarify this. Further data on a larger number of specimens and evaluation of
178clinical management based on HCMV-DNAemia results will allow for better definition of the
179performance characteristics and clinical validation.

180

181

182**Acknowledgments**

183This work was partially supported by Qiagen (Qiagen has provided reagents and a financial support
184to SM). The authors acknowledge Dr. Laura Arboit (Qiagen Italy) for technical support.

185References

- 186Freyer, J.F., Heath, A.B., Anderson, R., Minor, P.D., and the collaborative study group., 18-22
187October 2010. Collaborative study to evaluate the proposed 1st WHO international standard for
188human cytomegalovirus for nucleic acid amplification-based assays. WHO/BS/10.2138, pp 1-40.
189Geneva, Switzerland.
- 190Hirsch, H.H., Lautenschlager, I., Pinsky, B.A., Cardeñoso, L., Aslam, S., Cobb, B., Vilchez, R.A.,
191Valsamakis, A., 2013. An international multicenter performance analysis of cytomegalovirus load
192tests. Clin. Infect. Dis. 56, 367-373.
- 193Kotton, C.N., Kumar, D., Caliendo, A.M., Asberg, A., Chou, S., Snyderman, D.R., Allen, U., Humar,
194A., and the Transplantation Society International CMV Consensus Group., 2010. International
195consensus guidelines on the management of cytomegalovirus in solid organ transplantation.
196Transplantation. 89, 779-795.
- 197Kraft, C.S., Armstrong, W.S., Caliendo, A.M., 2012. Interpreting quantitative cytomegalovirus
198DNA testing: understanding the laboratory perspective. Clin. Infect. Dis. 54, 1793-1797.
- 199Lilleri, D., Lazzarotto, T., Ghisetti, V., Ravanini, P., Capobianchi, M.R., Baldanti, F., Gerna, G.,
200and the SIV-AMCLI Transplant Surveillance Group., 2009. Multicenter quality control study for
201human cytomegalovirus DNAemia quantification. New Microbiol. 32, 245-253.
- 202Zaia, J., Baden, L., Boeckh, M.J., Chakrabarti, S., Einsele, H., Ljungman, P., McDonald, G.B.,
203Hirsch, H., and the Center for International Blood and Marrow Transplant Research; National
204Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of
205Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious
206Disease Society of America; Society for Healthcare Epidemiology of America; Association of
207Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention.
2082009. Guidelines. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow
209Transplant. 44, 471-482.

210**Table 1**

211Performance characteristics of the two nucleic acid extraction and testing systems.

212

213

214	Features	System 1	System 2
	Target	MIE	MIE
	Extracted DNA volume in PCR reaction (µl)	20	5
	Final volume (µl) in assay	50	25
215	N ₀ , type of quantitation standards	4, plasmid	4, plasmid
	Analytical sensitivity*	164,55 copies/ml	158 copies/ml
216	Specificity*	100%	90%
	Linear range*	1x10 ³ -5x10 ⁷	20-1x10 ⁶ -
217		copies/ml	copies/reaction

218

219

220

221*Technical specifications as indicated in the manufacturer’s report.

222**Table 2**

223Detection of HCMV-DNA obtained by systems 1 and 2 on 189 whole blood specimens.

224

System 1				
System 2	POS		NEG	TOT 99
	POS	90 (47.6%)	9 (4.8%)	
	NEG	28 (14.8%)	62 (32.8%)	
	TOT 118			

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243**Table 3**

244System 1 and 2 variability within the QCMD 2012 HCMV proficiency panel.

Samples	System 1 results	System 2 results	QCMD results	Difference system 1 /	Difference system 2 /
	log ₁₀ (copies/ml)	log ₁₀ (copies/ml)	log ₁₀ (copies/ml)	QCMD log ₁₀ (copies/ml)	QCMD log ₁₀ (copies/ml)
CMV12-01	4.36	4.46	4.30	0.06	0.16
CMV12-02	3.89	3.86	3.74	0.15	0.12
CMV12-03	2.30	2.14	2.24	0.06	-0.10
CMV12-04	1.43	1.47	2.07	-0.64	-0.60
CMV12-05	2.99	3.40	2.90	0.09	0.50
CMV12-06	3.33	3.51	3.30	0.03	0.21
CMV12-07	3.50	3.50	3.32	0.18	0.18
CMV12-08	negative	negative	negative	/	/
CMV12-09	3.62	3.82	3.67	-0.05	0.15
CMV12-10	2.88	2.69	2.73	0.15	-0.04

246**Fig. 1.** Linear regression plot for log values of system 1 and system 2, by referring to the 90 double
247positive samples.

248
249**Fig. 2.** Mean differences in HCMV-DNA quantitation of 90 positive specimens with system 1 and 2
250by Bland-Altman analysis.

251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271

272**Figure 1**

273

274

275

276

277

278

279

280

281

282

283**Figure 2**